ArticleScientific reports2025
Quality of life changes after electrochemotherapy: a prospective single-center analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Rising Power of Electrochemotherapy in Musculoskeletal Oncology.Current oncology (Toronto, Ont.) · 2026Review
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- The Role of Electrochemotherapy in Managing Cutaneous Metastases from Breast Carcinoma: A Narrative Review.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of cutaneous and subcutaneous tumors has driven interest in electrochemotherapy (ECT) as a potential treatment. However, patient-reported outcomes remain underexplored. This study aims to assess the short-term impact of ECT on the quality of life (QoL) of patients, addressing a gap in the current literature. A prospective study evaluated 62 patients treated with ECT between 2015 and 2022. QoL was measured using the EQ-5D-3L questionnaire, calculating EQ-5D-index and assessing health state (EQ-VAS) and pain (pain-VAS). Subgroup analysis was conducted based on tumor histology, previous radiotherapy, and tumor size. Statistical analysis was performed using SPSS 29.0.0. The median age was 70 years, with a median follow-up of 47 days. Pre-treatment, 38.7% of patients reported pain/discomfort, and 24% had anxiety/depression. Post-treatment, these decreased to 32.2% and 19%, respectively. While the EQ-VAS and EQ-5D-3L scores showed a non-significant increase, pain-VAS decreased. Significant improvements were seen in patients with previous radiotherapy (EQ-VAS, p = 0.047; EQ-5D-index, p = 0.012) and smaller tumors (EQ-VAS, p = 0.035; pain-VAS, p = 0.029). ECT demonstrates a significant short-term benefit in maintaining or improving QoL in patients with cutaneous malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.